Cell-therapy due diligence for patients in Romania
A country-specific starting point for checking product authorisation, trial oversight and cross-border follow-up. This page does not rank providers or recommend medical travel.
What the regulator can confirm
Romania participates in the EU medicines and ATMP framework. The National Agency for Medicines and Medical Devices publishes clinical-trial information, while EMA records cover centrally authorised ATMPs. A trial record must be separated from routine marketing authorisation, and an EU location does not prove that a specific commercial intervention is lawful.
Request the exact product, indication, manufacturer, trial or authorisation number and the competent authority's confirmation. For treatment in another country, verify its separate legal route and arrange independent clinical review, insurance, emergency planning and continuity of care.
Evidence to request before treatment
| Question | Document or identifier | Why it matters |
|---|---|---|
| What exactly is administered? | Product name, cell source, processing, dose and route | Evidence and legal status are product- and indication-specific. |
| What is the legal route? | Marketing authorisation, authorised trial number, or named exemption and authority | A clinic licence or registry listing does not by itself authorise a product. |
| Who manufactures it? | Legal manufacturer, site and authorisation scope | General references to GMP are not a substitute for a current, applicable record. |
| How are harms managed? | Consent form, adverse-event plan, insurance and emergency contact | Experimental status does not remove the duty to disclose and manage risk. |
| What happens after travel? | Written follow-up plan and named clinician | Cross-border care can complicate continuity and reporting. |
Conditions compared
Educational regulatory orientation, reviewed in 2026. Verify current records directly with the authority and seek independent medical advice.